Showing 2151-2160 of 4166 results for "".
- Eyenovia and Arctic Vision Announce License Agreement to Develop and Commercialize Products in Greater China and South Koreahttps://modernod.com/news/eyenovia-and-arctic-vision-announce-license-agreement-to-develop-and-commercialize-products-in-greater-china-and-south-korea/2478143/Eyenovia and Arctic Vision announced that they have entered into an exclusive license agreement for Arctic Vision to develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Tai
- The Vision Council Files Joint Letter in Opposition of China 301 Tariffs, Will Testify on Thursdayhttps://modernod.com/news/the-vision-council-files-joint-letter-in-opposition-of-china-301-tariffs-will-testify-on-thursday/2476669/This weekend, The Vision Council, the American Academy of Ophthalmology, National Association of Opticians and Optometrists, Opticians Association of America, National Association of Vision Care Plans, Prevent Blindness, and OneSight jointly filed a letter to the United States Trade Representativ
- Johnson & Johnson Vision Presents New Data on Silicone Hydrogel Contact Lens Muco-Adhesive Propertieshttps://modernod.com/news/johnson-johnson-vision-presents-new-data-on-silicone-hydrogel-contact-lens-muco-adhesive-properties/2480192/Johnson & Johnson Vision presented new data at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Honolulu, Hawaii. The data measured how the extent of crosslinking affects muco-adhesion in a laboratory study with corneal epithel
- Johnson & Johnson Vision Highlights New Data at 2018 ARVO Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-highlights-new-data-at-2018-arvo-annual-meeting/2480201/Johnson & Johnson Vision announced that a suite of new research from its eye health portfolio will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Honolulu, Hawaii from April 29 to M
- More than 240 Exhibitors Commit to Vision Expo East 2022, Taking Place In-Person from March 31–April 3 at the Javits Centerhttps://modernod.com/news/more-than-240-exhibitors-commit-to-vision-expo-east-2022-taking-place-in-person-from-march-31-april-3-at-the-javits-center/2480582/The organizers of Vision Expo, The Vision Council and RX, share that more than 240 exhibitors have committed to Vision Expo East to-date. Vision Expo East 2022 will take place from March 31–April 3 at the Jacob Javits Center in New York City. &l
- EyePrint Prosthetics Announces Clinical Outcomes Achieved With EyePrintPROhttps://modernod.com/news/eyeprint-prosthetics-announces-clinical-outcomes-achieved-with-eyeprintpro/2480203/EyePrint Prosthetics, a company dedicated to restoring vision to patients who have complex corneal irregularities, announced the clinical outcomes that have been achieved since the EyePrintPRO lens was FDA-cleared 2 y
- Opus Genetics Phase 3 Trial for Phentolamine Ophthalmic Solution Meets Primary Endpoint for Night Visionhttps://modernod.com/news/opus-genetics-phase-3-trial-for-phentolamine-ophthalmic-solution-meets-primary-endpoint-for-night-vision/2482828/Opus Genetics announced positive topline results from LYNX-2, a phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Patients who undergo kera
- Notal Vision Announces Results From Prospective Trial Using Home-Based OCThttps://modernod.com/news/notal-vision-announces-results-from-prospective-trial-using-home-based-oct/2482331/Notal Vision announced the results from the first prospective clinical trial using home-based optical coherence tomography (OCT) to manage wet age-related macular degeneration (AMD) patients in an investigational setting. The results, which were published in Retina, demonstrated a
- OnPoint Vision Initiates Phase 1 Trial of AccuraSee Intraocular Pseudophakic Capsular Lens Magnifierhttps://modernod.com/news/onpoint-vision-initiates-phase-1-trial-of-accurasee-intraocular-pseudophakic-capsular-lens-magnifier/2482184/OnPoint Vision announced open enrollment of the phase 1 IDE clinical trial of the AccuraSee Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG) for secondary implantation in the capsular bag with a pre-existing 6mm acrylic posterior chamber IOL. The IOPCL MAG is neu
- FDA Approves OnPoint Vision’s IDE Application to Begin Phase 1 of IOPCL Magnifierhttps://modernod.com/news/fda-approves-onpoint-visions-ide-application-to-begin-phase-1-of-iopcl-magnifier/2481925/OnPoint Vision announced the FDA approval of their investigational device exemption (IDE) application to begin phase 1 of their pivotal clinical trial of the AccuraSee Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG) for secondary implantation in the capsular bag with